Hepion Pharmaceuticals Licenses Novel ctRNA Assay, Pivoting to Liquid Biopsy Diagnostics

summarizeSummary

Hepion Pharmaceuticals has in-licensed a novel circulating tumor RNA (ctRNA) biomarker assay for early diagnosis of liver cancer, marking a strategic pivot towards precision liquid biopsy diagnostics.

check_boxKey Events

• Strategic Pivot to Diagnostics

  Hepion Pharmaceuticals announced a strategic shift to focus on advancing clinically proven liquid biopsy tests for early cancer detection, led by CEO Dr. Kaouthar Lbiati.

• In-licensing of ctRNA Assay

  The company in-licensed a novel circulating tumor RNA (ctRNA) biomarker assay from Cirna Diagnostics, LLC, designed for early diagnosis of hepatocellular carcinoma (HCC) in high-risk patients.

• Material Agreement Terms

  The licensing agreement includes an upfront payment of $50,000, potential patent milestone payments up to $2.35 million, sales milestone payments up to $4.5 million, and low single-digit royalties on net sales.

• Complementary Product Pipeline

  This new ctRNA platform augments Hepion's growing pipeline, complementing its recently acquired mSEPT9 PCR-based assay for liver cancer detection.

auto_awesomeAnalysis

Hepion Pharmaceuticals, a nano-cap company, has entered into a material definitive agreement to in-license a novel circulating tumor RNA (ctRNA) biomarker assay for the early diagnosis of hepatocellular carcinoma (HCC). This move signifies a critical strategic pivot for the company towards precision liquid biopsy diagnostics, complementing its existing mSEPT9 assay. The agreement includes an upfront payment of $50,000 and substantial potential milestone payments totaling up to $6.85 million, plus royalties. For a company of Hepion's size, this represents a significant investment and a clear new direction under its CEO, Dr. Kaouthar Lbiati, aiming to capitalize on the growing $10 billion liquid biopsy market. This strategic shift could be transformative for the company's future.